Drug
NI 0501
NI 0501: highest development phase Phase 2/3, developed by Swedish Orphan Biovitrum. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Swedish Orphan Biovitrum
Trials
| Drug | Phase | Indication |
|---|---|---|
| NI-0501 NCT01818492 | Phase 2/3 | Primary Haemophagocytic Lymphohistiocytosis |
| NI-0501 NCT04765553 | Phase 1 | Rare Diseases |
Latest
No recent events.
Follow NI 0501 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.